Related Experiment Videos
Bacterial peritonitis and beta-2 microglobulin (B2M) production by peritoneal macrophages (PM0) in CAPD patients
S Carozzi1, M G Nasini, C Schelotto
1Nephrology and Dialysis Unit, St. Paul's Hospital, Savona, Italy.
Abstract:
To evaluate the role of bacterial peritonitis in peritoneal macrophage (PMO) Beta-2 Microglobulin (B2M) production and its relationship with PMO Interleukin-1 (IL-1) and Leukotriene B4 (LTB4) release we analyzed in 20 CAPD patients (10 with peritonitis): 1. in vivo plasma and peritoneal dialysis effluent (PDE) B2M, IL-1 and LTB4 levels; 2. in vitro B2M, IL-1 and LTB4 release by PMO. Values were compared with those seen in the plasma or with peripheral blood monocytes of 30 hemodialysis (HD) patients (10 treated with Cuprophan-CU-, 10 with Polyacrylonitrile - PAN, and 10 with Cellulose Acetate - CA). Results showed that in CAPD patients with bacterial peritonitis B2M, IL-1 and LTB4 concentrations in the PDE were significantly higher than those seen in CAPD patients without peritonitis or in the plasma of HD patients treated with PAN or CA, but were similar to those seen in HD patients treated with CU. At the same time, in vitro, PMO from CAPD patients with bacterial peritonitis produced more B2M, IL-1 and LTB4 than did PMO from CAPD patients without peritonitis or peripheral blood monocytes from HD patients treated with PAN or CA. We conclude that in CAPD patients bacterial peritonitis is able to induce PMO B2M production, probably via a cytokine-mediated process, which may be analogous to what occurs with peripheral blood monocytes of HD patients treated with CU.
Insights
Bacterial peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients significantly increases peritoneal macrophage (PMO) production of Beta-2 Microglobulin (B2M), Interleukin-1 (IL-1), and Leukotriene B4 (LTB4). This suggests a cytokine-mediated process linked to dialysis membrane interactions.
Area of Science:
- Nephrology
- Immunology
- Peritoneal Dialysis
Background:
- Bacterial peritonitis is a common complication in continuous ambulatory peritoneal dialysis (CAPD).
- Peritoneal macrophages (PMO) play a crucial role in the inflammatory response during peritonitis.
- Beta-2 Microglobulin (B2M), Interleukin-1 (IL-1), and Leukotriene B4 (LTB4) are key inflammatory mediators.
Purpose of the Study:
- To investigate the impact of bacterial peritonitis on Beta-2 Microglobulin (B2M) production by peritoneal macrophages (PMO) in CAPD patients.
- To examine the relationship between B2M production and the release of Interleukin-1 (IL-1) and Leukotriene B4 (LTB4) by PMO during peritonitis.
- To compare these inflammatory markers in CAPD patients with and without peritonitis, and with hemodialysis (HD) patients.
Main Methods:
- Analysis of in vivo plasma and peritoneal dialysis effluent (PDE) levels of B2M, IL-1, and LTB4 in 20 CAPD patients (10 with peritonitis).
- In vitro assessment of B2M, IL-1, and LTB4 release by PMO isolated from CAPD patients.
- Comparison of results with plasma and peripheral blood monocytes from 30 hemodialysis (HD) patients using different dialysis membranes (Cuprophan, Polyacrylonitrile, Cellulose Acetate).
Main Results:
- CAPD patients with bacterial peritonitis exhibited significantly higher PDE concentrations of B2M, IL-1, and LTB4 compared to those without peritonitis.
- These elevated levels in peritonitis patients were comparable to HD patients treated with Cuprophan but higher than those treated with Polyacrylonitrile or Cellulose Acetate.
- In vitro studies confirmed that PMO from CAPD patients with peritonitis produced greater amounts of B2M, IL-1, and LTB4.
Conclusions:
- Bacterial peritonitis in CAPD patients induces significant B2M production by peritoneal macrophages (PMO).
- This induction is likely mediated by cytokines and may share similarities with inflammatory responses observed in hemodialysis patients exposed to certain dialysis membranes (Cuprophan).
- Understanding these inflammatory pathways is crucial for managing peritonitis and optimizing dialysis strategies.